STOCK TITAN

Notice of General Meeting

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Biodexa Pharmaceuticals (Nasdaq: BDRX) announces a General Meeting scheduled for November 22, 2024, at 13:00 GMT in Cardiff. The Board proposes two key resolutions: 1) subdividing each issued ordinary share of £0.001 into one ordinary share of £0.00005 and 19 C deferred shares of £0.00005, and 2) adopting new articles of association. The purpose is to lower the par value of ordinary shares to enable share issuance above par value. The company confirms that these changes won't affect the number of outstanding ordinary shares or American Depositary Shares.

Biodexa Pharmaceuticals (Nasdaq: BDRX) annuncia un'Assemblea Generale programmata per il 22 novembre 2024, alle 13:00 GMT a Cardiff. Il Consiglio propone due risoluzioni chiave: 1) suddividere ogni azione ordinaria emessa di £0.001 in un'azione ordinaria di £0.00005 e 19 azioni differite di £0.00005, e 2) adottare nuovi articoli di associazione. L'obiettivo è quello di abbassare il valore nominale delle azioni ordinarie per consentire l'emissione di azioni a un valore superiore al valore nominale. L'azienda conferma che queste modifiche non influenzeranno il numero di azioni ordinarie in circolazione o di American Depositary Shares.

Biodexa Pharmaceuticals (Nasdaq: BDRX) anuncia una Junta General programada para el 22 de noviembre de 2024, a las 13:00 GMT en Cardiff. La Junta propone dos resoluciones clave: 1) dividir cada acción ordinaria emitida de £0.001 en una acción ordinaria de £0.00005 y 19 acciones diferidas de £0.00005, y 2) adoptar nuevos estatutos. El propósito es reducir el valor nominal de las acciones ordinarias para permitir la emisión de acciones por encima del valor nominal. La empresa confirma que estos cambios no afectarán el número de acciones ordinarias en circulación ni de American Depositary Shares.

Biodexa Pharmaceuticals (Nasdaq: BDRX)는 2024년 11월 22일 오후 1시 GMT에 카디프에서 예정된 총회를 발표했습니다. 이사회는 두 가지 주요 결의를 제안합니다: 1) £0.001의 발행된 보통주를 £0.00005의 보통주 1주와 £0.00005의 19 C 보류주로 분할하고, 2) 새로운 정관을 채택하는 것입니다. 목적은 보통주의 액면가를 낮추어 액면가 이상의 주식 발행을 가능하게 하는 것입니다. 회사는 이러한 변경이 발행된 보통주 또는 미국 예탁 증권의 수에 영향을 미치지 않을 것이라고 확인했습니다.

Biodexa Pharmaceuticals (Nasdaq: BDRX) annonce une Assemblée Générale prévue pour le 22 novembre 2024 à 13h00 GMT à Cardiff. Le Conseil propose deux résolutions clés : 1) de diviser chaque action ordinaire émise d'une valeur de £0.001 en une action ordinaire d'une valeur de £0.00005 et 19 actions différées d'une valeur de £0.00005, et 2) d'adopter de nouveaux statuts. L'objectif est de réduire la valeur nominale des actions ordinaires pour permettre l'émission d'actions au-dessus de leur valeur nominale. La société confirme que ces changements n'affecteront pas le nombre d'actions ordinaires ou d'American Depositary Shares en circulation.

Biodexa Pharmaceuticals (Nasdaq: BDRX) kündigt eine Hauptversammlung an, die für den 22. November 2024 um 13:00 Uhr GMT in Cardiff geplant ist. Der Vorstand schlägt zwei wichtige Beschlüsse vor: 1) jede ausgegebene Stammaktie im Wert von £0.001 in eine Stammaktie im Wert von £0.00005 und 19 C-Teile im Wert von £0.00005 aufzuteilen und 2) neue Satzungen zu verabschieden. Ziel ist es, den Nennwert der Stammaktien zu senken, um die Ausgabe von Aktien über dem Nennwert zu ermöglichen. Das Unternehmen bestätigt, dass diese Änderungen die Anzahl der ausstehenden Stammaktien oder American Depositary Shares nicht beeinträchtigen werden.

Positive
  • None.
Negative
  • None.

November 7, 2024

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

Notice of General Meeting

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 22 November 2024 at 13:00 GMT was posted to shareholders yesterday.

The Board of Directors is proposing two resolutions:

Ordinary Resolution

      1.   That, subject to and conditional on the passing of Resolution 2, each of the issued ordinary shares of £0.001 each in the capital of the Company be subdivided and redesignated into one ordinary share of £0.00005 each and 19 C deferred shares of £0.00005 each (such C deferred shares having the rights and being subject to the restrictions set out in the articles of association of the Company adopted pursuant to Resolution 2).


Special Resolution
      2.   That, subject to and conditional on the passing of Resolution 1, the draft articles of association tabled at the meeting, initialled by the Chairman, and available on the Company’s website, www.biodexapharma.com and labelled the ‘New Articles’, be approved and adopted as the new articles of association of the Company in substitution for and to the entire exclusion of the Company’s existing articles of association.

The purpose of the Resolutions is to lower the par value of the ordinary shares and allow the Company to issue ordinary shares above par value.

Neither the number of ordinary shares outstanding nor the number of American Depositary Shares will change as a result of passing of the Resolutions.

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.

eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.

Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.

MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.

Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.

 Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.

Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

 

FAQ

When is Biodexa Pharmaceuticals (BDRX) holding its General Meeting in November 2024?

Biodexa Pharmaceuticals is holding its General Meeting on November 22, 2024, at 13:00 GMT at the Company's offices in Cardiff.

What are the two resolutions proposed by BDRX at the November 2024 General Meeting?

The two resolutions are: 1) subdividing each ordinary share into one ordinary share and 19 C deferred shares of £0.00005 each, and 2) adopting new articles of association.

Will BDRX's share subdivision affect the number of outstanding shares?

No, neither the number of ordinary shares outstanding nor the number of American Depositary Shares will change as a result of passing the resolutions.

Biodexa Pharmaceuticals plc American Depositary Shs

NASDAQ:BDRX

BDRX Rankings

BDRX Latest News

BDRX Stock Data

2.72M
521.84k
10.16%
21.03%
2.37%
Biotechnology
Healthcare
Link
United States of America
Cardiff